Novo Nordisk's Wegovy gets accelerated US FDA approval for liver disease MASH
1. NVO's Wegovy received FDA accelerated approval for treating liver disease. 2. This expands the drug’s market potential significantly.
FAQ
Why Very Bullish?
The approval could lead to increased revenue streams, similar to how past drug approvals have surged stock prices.
How important is it?
FDA approval for a new indication can drastically impact revenues, especially in weight management and liver disease sectors.
Why Long Term?
The long-term effects will manifest as prescription rates increase over time and market share is gained.